Cite

HARVARD Citation

    Moss, R. et al. (2015). Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet. 3 (7), pp. 524-533. [Online]. 
  
Back to record